Pamiparib

CAS No. 1446261-44-4

Pamiparib( BGB-290 | BGB 290 )

Catalog No. M11894 CAS No. 1446261-44-4

Pamiparib (BGB-290, BGB290) is a?highly potent, selective and brain penetrant PARP1/2 inhibitor with potent anti-tumor activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 36 In Stock
5MG 45 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Pamiparib
  • Note
    Research use only, not for human use.
  • Brief Description
    Pamiparib (BGB-290, BGB290) is a?highly potent, selective and brain penetrant PARP1/2 inhibitor with potent anti-tumor activity.
  • Description
    Pamiparib (BGB-290, BGB290) is a?highly potent, selective and brain penetrant PARP1/2 inhibitor with potent anti-tumor activity.Ovarian Cancer Phase 2 Clinical(In Vitro):Pamiparib shows potent DNA-trapping activity with an IC50 of 13 nM. In the cellular assays, Pamiparib inhibits intracellular PAR formation with an IC50 of 0.24 nM. Tumor cell lines with homologous recombination defects are profoundly sensitive to Pamiparib. Pamiparib is highly active both in vitro and in vivo in BRCA mutant tumors.(In Vivo):Pamiparib suppresses PARP activity in patient-derived glioblastoma multiforme and small-cell-lung cancer xenografts, and potentiates the effects of Temozolamide. In vivo activities of Pamiparib, and its combination activity with chemotherapies in patient biopsy derived small cell lung cancer (SCLC) xenograft models.
  • In Vitro
    Pamiparib shows potent DNA-trapping activity with an IC50 of 13 nM. In the cellular assays, Pamiparib inhibits intracellular PAR formation with an IC50 of 0.24 nM. Tumor cell lines with homologous recombination defects are profoundly sensitive to Pamiparib. Pamiparib is highly active both in vitro and in vivo in BRCA mutant tumors.
  • In Vivo
    Pamiparib suppresses PARP activity in patient-derived glioblastoma multiforme and small-cell-lung cancer xenografts, and potentiates the effects of Temozolamide. In vivo activities of Pamiparib, and its combination activity with chemotherapies in patient biopsy derived small cell lung cancer (SCLC) xenograft models.
  • Synonyms
    BGB-290 | BGB 290
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    PARP
  • Recptor
    PARP
  • Research Area
    Cancer
  • Indication
    Ovarian Cancer

Chemical Information

  • CAS Number
    1446261-44-4
  • Formula Weight
    298.32
  • Molecular Formula
    C16H15FN4O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 83.3 mg/mL 279.24 mM
  • SMILES
    CC12CCCN1CC3=NNC(=O)C4=C5C3=C2NC5=CC(=C4)F
  • Chemical Name
    (10aR)-2-fluoro-10a-methyl-5,8,9,10,10a,11-hexahydro-5,6,7a,11- tetraazacyclohepta[def]cyclopenta[a]fluoren-4(7H)-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Fluzoparib

    fluzoparib is a novel, potent, and orally available inhibitor of PARP, potentially for the treatment of solid tumours.Fluzoparib potently inhibited PARP1 enzyme activity and induced DNA double-strand breaks, G2 /M arrest, and apoptosis in homologous recombination repair (HR)-deficient cells.?

  • Rucaparib phosphate

    An inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay.

  • NVP-BVU972

    NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.